Evidence reviews – March 2018
In March 2018, we reviewed the evidence for attention deficit hyperactivity disorder: diagnosis and management in the following areas:
- Risk factors
- Information and support
- Pharmacological efficacy and sequencing
- Pharmacological safety
- Non-pharmacological efficacy and adverse events
- Combination treatment
- Adherence to treatment
- Managing treatment
- Withdrawal and drug holidays
See the guideline scope for more information about why we decided to update the guideline.
This page was last updated: